{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:36:01Z","timestamp":1793597761209,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T044934\/1"],"award-info":[{"award-number":["MR\/T044934\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1491\/A25351"],"award-info":[{"award-number":["C1491\/A25351"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTUQQR-Dec22\/100004"],"award-info":[{"award-number":["CTUQQR-Dec22\/100004"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eclinm.2024.102987","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:46:06Z","timestamp":1736538366000},"page":"102987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-3864","authenticated-orcid":false,"given":"Jan","family":"Rekowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Solovyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-6920","authenticated-orcid":false,"given":"Munyaradzi","family":"Dimairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Rouhifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4113-2726","authenticated-orcid":false,"given":"Dhrusti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-7439","authenticated-orcid":false,"given":"Emily","family":"Alger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-837X","authenticated-orcid":false,"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Wen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney H.","family":"Coschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garrett\u2013Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-072X","authenticated-orcid":false,"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kholmanskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kightley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Matcham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija Rerhou","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn P.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Ursino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib2","doi-asserted-by":"crossref","first-page":"e068173","DOI":"10.1136\/bmjopen-2022-068173","article-title":"SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol","volume":"13","author":"Espinasse","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12916-023-02937-0","article-title":"Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study","volume":"21","author":"Solovyeva","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2024.102987_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102228","article-title":"Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review","volume":"64","author":"Alger","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib6","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.21873\/anticanres.16076","article-title":"Phase I CAR-T clinical trials review","volume":"42","author":"Bulsara","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eclinm.2024.102987_bib7","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.annonc.2022.01.018","article-title":"53P Assessing the reporting quality of early phase dose-finding trials","volume":"33","author":"Yap","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102987_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107277","article-title":"Reporting quality of CONSORT flow diagrams in published early phase dose-finding clinical trial reports: improvement is needed","volume":"131","author":"Alger","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eclinm.2024.102987_bib10","doi-asserted-by":"crossref","first-page":"e076387","DOI":"10.1136\/bmj-2023-076387","article-title":"Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102987_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib12","doi-asserted-by":"crossref","first-page":"e1000217","DOI":"10.1371\/journal.pmed.1000217","article-title":"Guidance for developers of health research reporting guidelines","volume":"7","author":"Moher","year":"2010","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102987_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102987_bib14","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102987_bib15","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M17-0046","article-title":"CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts","volume":"167","author":"Boutron","year":"2017","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102987_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/ijs.12548","article-title":"A\u00a0Phase 1 exercise dose escalation study for stroke survivors with impaired walking","volume":"10","author":"Dite","year":"2015","journal-title":"Int J Stroke"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","article-title":"A\u00a0phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours","volume":"119","author":"Schram","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-019-2008-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects","volume":"21","author":"Danto","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10240","key":"10.1016\/j.eclinm.2024.102987_bib22","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib23","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1371\/journal.pmed.0050020","article-title":"CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration","volume":"5","author":"Hopewell","year":"2008","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10637-017-0549-6","article-title":"Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database","volume":"36","author":"Shepshelovich","year":"2017","journal-title":"Invest N Drugs"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/1078-0432.CCR-07-4886","article-title":"Improving the quality of abstract reporting for phase I cancer trials","volume":"14","author":"Strevel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102987_bib26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF-MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.eclinm.2024.102987_bib28","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.21.02125","article-title":"Ethical considerations for phase I trials in oncology","volume":"40","author":"Bittlinger","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11948-022-00418-w","article-title":"States of uncertainty, risk-benefit assessment and early clinical research: a Conceptual investigation","volume":"28","author":"Schnarr","year":"2022","journal-title":"Sci Eng Ethics"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib31","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2665-9913(21)00061-8","article-title":"Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial","volume":"3","author":"Pratt","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","article-title":"A\u00a0phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance","volume":"29","author":"Yap","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102987_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ymeth.2020.01.011","article-title":"In silico trials: verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products","volume":"185","author":"Viceconti","year":"2021","journal-title":"Methods"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102987_bib35","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib36","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102987_bib37","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1158\/1078-0432.CCR-06-2860","article-title":"Trends in the use and role of biomarkers in phase I oncology trials","volume":"13","author":"Goulart","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4155\/bio-2018-0006","article-title":"Biomarkers in early-phase trials: fundamental issues","volume":"10","author":"Yee","year":"2018","journal-title":"Bioanalysis"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102987_bib40","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bcp.15914","article-title":"Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: results from the first-in-human study in healthy adults","volume":"90","author":"Boof","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102987_bib42","article-title":"A\u00a0phase 1 study of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of V-7404 in healthy adult volunteers","volume":"65","author":"Kankam Martin","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102987_bib43","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.31574","article-title":"Pragmatic approaches to address expansion cohort design","volume":"124","author":"Dahlberg","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102987_bib44","doi-asserted-by":"crossref","first-page":"e068177","DOI":"10.1136\/bmj-2021-068177","article-title":"Early phase clinical trials extension to guidelines for the content of statistical analysis plans","volume":"376","author":"Homer","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/sim.6910","article-title":"Implementation of adaptive methods in early-phase clinical trials","volume":"36","author":"Petroni","year":"2017","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A\u00a0Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12890-018-0763-9","article-title":"A\u00a0phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers","volume":"19","author":"Staton","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib48","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10637-021-01141-2","article-title":"Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors","volume":"39","author":"Italiano","year":"2021","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.eclinm.2024.102987_bib49","doi-asserted-by":"crossref","first-page":"m115","DOI":"10.1136\/bmj.m115","article-title":"The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib50","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/cancers14061566","article-title":"A\u00a0brief overview of adaptive designs for phase I cancer trials","volume":"14","author":"Saxena","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A\u00a0phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib53","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-017-2226-2","article-title":"Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants","volume":"73","author":"Lee","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"10306","key":"10.1016\/j.eclinm.2024.102987_bib54","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.eclinm.2024.102987_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2288-14-84","article-title":"Three steps to writing adaptive study protocols in the early phase clinical development of new medicines","volume":"14","author":"Lorch","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib58","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102987_bib59","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":"Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study","volume":"18","author":"Moss\u00e9","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.2004.03.129","article-title":"Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer","volume":"22","author":"Muler","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12874-018-0638-z","article-title":"How to design a dose-finding study using the continual reassessment method","volume":"19","author":"Wheeler","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2024.102987_bib63","article-title":"Model-assisted designs for early-phase clinical trials: simplicity meets superiority","volume":"3","author":"Yuan","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib64","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.22.01736","article-title":"Ethics and clinical research: improving transparency and informed consent in phase I oncology trials","volume":"41","author":"Frankel","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00441","article-title":"Handling incomplete or late-onset toxicities in early-phase dose-finding clinical trials: current practice and future prospects","author":"Yin","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.792","article-title":"A\u00a0first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers","volume":"9","author":"Sj\u00f6berg","year":"2021","journal-title":"Pharm Res Perspect"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102987_bib67","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881120914206","article-title":"Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial","volume":"34","author":"Recourt","year":"2020","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102987_bib68","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.2147\/DDDT.S121520","article-title":"Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013","volume":"10","author":"Suh","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.yrtph.2010.06.007","article-title":"Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals","volume":"58","author":"Tibbitts","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib72","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European medicines agency review of kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.eclinm.2024.102987_bib73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.07.006","article-title":"Clinical development of cell therapies for cancer: the regulators' perspective","volume":"138","author":"Exley","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrclinonc.2013.35","article-title":"Adaptive designs for dual-agent phase I dose-escalation studies","volume":"10","author":"Harrington","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdu516","article-title":"Designs of drug-combination phase I trials in oncology: a systematic review of the literature","volume":"26","author":"Riviere","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102987_bib76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.604","article-title":"Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers","volume":"8","author":"Yang","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib78","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A\u00a0randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","article-title":"The changing landscape of phase I trials in oncology","volume":"13","author":"Wong","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pst.1801","article-title":"Statistical issues in first-in-human studies on BIA 10-2474: neglected comparison of protocol against practice","volume":"16","author":"Bird","year":"2017","journal-title":"Pharm Stat"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033009","article-title":"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol","volume":"10","author":"Kong","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib83","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s44276-023-00026-6","article-title":"Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer","volume":"2","author":"Kong","year":"2024","journal-title":"BJC Reports"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13063-021-05384-5","article-title":"TRAFIC: statistical design and analysis plan for a pragmatic early phase 1\/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis","volume":"22","author":"Cole","year":"2021","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib85","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/cas.14265","article-title":"First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"111","author":"Koyama","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib87","first-page":"634","article-title":"Safety and pharmacokinetics of sodium nitrite in patients with subarachnoid hemorrhage: a phase IIa study","volume":"119","author":"Oldfield","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib88","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0091270003252243","article-title":"Evaluation of the cohort size in phase I dose escalation trials based on laboratory data","volume":"43","author":"Bu\u00f6en","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102987_bib89","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-17-0582","article-title":"Dose transition pathways: the missing link between complex dose-finding designs and simple decision-making","volume":"23","author":"Yap","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib90","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","article-title":"First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2","volume":"4","author":"Smit","year":"2023","journal-title":"Lancet Microbe"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib91","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A\u00a0phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102987_bib92","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/annonc\/mdl071","article-title":"A\u00a0phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours","volume":"17","author":"Dumez","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib93","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A\u221702+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib94","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib95","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/sim.6894","article-title":"Sequential monitoring of Phase I dose expansion cohorts","volume":"36","author":"Iasonos","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102987_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106605","article-title":"Controlled backfill in oncology dose-finding trials","volume":"111","author":"Dehbi","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/19466315.2015.1135185","article-title":"Dose expansion cohorts in Phase I trials","volume":"8","author":"Iasonos","year":"2016","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.eclinm.2024.102987_bib99","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e\u2013flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102987_bib100","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1016\/S2352-3026(21)00273-8","article-title":"Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study","volume":"8","author":"Rutherford","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1745-6215-13-173","article-title":"A\u00a0theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries","volume":"13","author":"Kimmelman","year":"2012","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement","volume":"326","author":"Orkin","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bcp.15910","article-title":"Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: central nervous system depression and pseudo-hallucinations","volume":"90","author":"Dijkstra","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib106","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/bcp.14187","article-title":"First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects","volume":"86","author":"Banfield","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"mar07 3","key":"10.1016\/j.eclinm.2024.102987_bib107","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib108","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1038\/s41598-022-24057-0","article-title":"Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer","volume":"13","author":"Kato","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-016-2189-8","article-title":"Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials","volume":"73","author":"Breithaupt-Groegler","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102987_bib110","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102987_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib112","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"issue":"28","key":"10.1016\/j.eclinm.2024.102987_bib113","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1002\/sim.8361","article-title":"A\u00a0utility-based Bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose for targeted and immune therapies","volume":"38","author":"Zhou","year":"2019","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib114","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.386","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects","volume":"7","author":"Bhattacharya","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102987_bib115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102987_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106517","article-title":"Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols","volume":"108","author":"Wages","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib117","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-014-2593-7","article-title":"Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors","volume":"74","author":"Brennan","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2024.102987_bib118","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13063-016-1489-8","article-title":"A\u00a0phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers","volume":"17","author":"Green","year":"2016","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib119","article-title":"Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)","volume":"9","author":"Slingluff","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A\u00a0phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib121","article-title":"Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma","volume":"9","author":"Patel","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib122","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcph.404","article-title":"Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability","volume":"55","author":"Glue","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib123","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-20-4730","article-title":"Phase I study of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas","volume":"27","author":"Wu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102987_bib124","article-title":"Two-stage single-arm trials are rarely analyzed effectively or reported adequately","volume":"5","author":"Grayling","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2024.102987_bib125","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-17-3716","article-title":"Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors","volume":"24","author":"Von Hoff","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102987_bib126","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib127","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/15459683211019362","article-title":"Multidimensional phase I dose ranging trials for stroke recovery interventions: key challenges and how to address them","volume":"35","author":"Dalton","year":"2021","journal-title":"Neurorehabilitation Neural Repair"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib128","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1038\/s41467-022-33267-z","article-title":"A\u00a0single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.vaccine.2014.06.006","article-title":"A\u00a0novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety","volume":"33","author":"Francis","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100938","article-title":"80MO Optimising participant flow diagrams for phase I clinical trials","volume":"8","author":"Alger","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2024.102987_bib131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1745-6215-12-253","article-title":"Reporting of participant flow diagrams in published reports of randomized trials","volume":"12","author":"Hopewell","year":"2011","journal-title":"Trials"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102987_bib132","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1111\/1759-7714.14713","article-title":"Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: a multicenter phase 1b\/2 trial","volume":"13","author":"Li","year":"2022","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib133","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00280-011-1588-x","article-title":"Final results of a prematurely discontinued Phase 1\/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma","volume":"68","author":"de Lima Lopes","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2024.102987_bib134","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2022.02.008","article-title":"Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1\/2 trial","volume":"169","author":"Bonomo","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eclinm.2024.102987_bib135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.oraloncology.2017.05.008","article-title":"A\u00a0phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN)","volume":"71","author":"Camille","year":"2017","journal-title":"Oral Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102987_bib136","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40360-017-0123-z","article-title":"Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers","volume":"18","author":"Chandorkar","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102987_bib138","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126054","article-title":"Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes","volume":"4","author":"Herold","year":"2019","journal-title":"JCI Insight"},{"issue":"29","key":"10.1016\/j.eclinm.2024.102987_bib139","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.12.0592","article-title":"Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer","volume":"25","author":"Desai","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"51","key":"10.1016\/j.eclinm.2024.102987_bib140","doi-asserted-by":"crossref","first-page":"84736","DOI":"10.18632\/oncotarget.12450","article-title":"A\u00a0phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors","volume":"7","author":"Pearson","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib141","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/nau.24272","volume":"39","author":"Rovner","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102987_bib142","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2016.08.017","article-title":"A\u00a0phase I\/II study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma","volume":"22","author":"Biran","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102987_bib143","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1158\/1078-0432.CCR-18-0421","article-title":"A\u00a0phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102987_bib144","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102987_bib146","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/djab017","article-title":"Patient-reported outcomes for tolerability assessment in phase I cancer clinical trials","volume":"113","author":"Basch","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102987_bib147","doi-asserted-by":"crossref","first-page":"e057712","DOI":"10.1136\/bmjopen-2021-057712","article-title":"Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study","volume":"12","author":"Retzer","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102987_bib148","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102987_bib149","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.eclinm.2024.102987_bib152","author":"GlaxoSmithKline"},{"issue":"25","key":"10.1016\/j.eclinm.2024.102987_bib153","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib154","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd.2017.65","article-title":"Trial watch: trends in clinical trial design complexity","volume":"16","author":"Getz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102987_bib157","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd.2016.85","article-title":"Trends in clinical success rates","volume":"15","author":"Smietana","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102987_bib158","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41591-021-01594-1","article-title":"The need for reporting guidelines for early phase dose-finding trials: dose-finding CONSORT Extension","volume":"28","author":"Yap","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib159","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s43441-019-00061-x","article-title":"Choosing estimands in clinical trials: putting the ICH E9(R1) into practice","volume":"54","author":"Ratitch","year":"2020","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102987_bib160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s43441-019-00065-7","article-title":"Defining efficacy estimands in clinical trials: examples illustrating ICH E9(R1) guidelines","volume":"54","author":"Ratitch","year":"2020","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102987_bib161","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/pst.2319","article-title":"Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development","volume":"22","author":"Englert","year":"2023","journal-title":"Pharm Stat"},{"key":"10.1016\/j.eclinm.2024.102987_bib162","first-page":"1","article-title":"Estimands in oncology early\u00a0clinical development: assessing the impact of intercurrent events on the dose-toxicity relationship","author":"Mercier","year":"2024","journal-title":"Stat Biopharm Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T20:10:36Z","timestamp":1750450236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024005662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":148,"alternative-id":["S2589537024005662"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102987","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102987"}}